Navigation Links
Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
Date:2/21/2012

DSMB) met for the fifth time to review the available safety data and recommended the study continue without change.  VISTA-16 is a Phase 3 pivotal clinical study evaluating the benefit of early varespladib treatment in high-risk ACS patients.  As per a Special Protocol Assessment with FDA, the primary endpoint of the VISTA-16 study is a reduction in Major Adverse Cardiovascular Events (MACE) as defined by FDA draft guidance to include cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or documented unstable angina with objective evidence of ischemia requiring hospitalization.  Details regarding the study can be found at http://www.clinicaltrials.gov.
  • In the fourth quarter of 2011, the VISTA-16 study accrued the requisite one hundred and ninety-three (193) adjudicated primary endpoint events required for the pre-specified interim efficacy analysis.  Subsequent to the end of the fourth quarter, the DSMB scheduled a meeting for the second week in March 2012 to review all available safety data and to conduct the formal interim efficacy analysis.  The interim efficacy analysis plan for the VISTA-16 clinical study allows for a recommendation by the DSMB to stop the study should there be sufficient evidence of overwhelming treatment benefit in the varespladib arm after approximately 193 of the primary events have been accrued.  Overwhelming benefit is defined as a treatment effect in favor of the varespladib arm resulting in a p-value of less than 0.001 (p<0.001).
  • Enrollment in the Phase 2b PEARL-SC clinical study was completed (N=547) in the fourth quarter. The PEARL-SC study is examining the therapeutic benefit of monthly and weekly subcutaneous doses of blisibimod in patients with lupus.  The primary endpoint of PEARL-SC requires patients to demonstrate a greater than or equal to five (>/=5) point reduction in the SELENA-SLEDAI clinical assessment s
    '/>"/>

  • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... --  Surefire Medical , Inc., the developer of a ... delivery of embolization agents in minimally invasive direct-to-tumor interventional ... R. Daniels , MD of the University of Southern ... Steven C. Katz , MD of the Roger Williams ... (SAB).    "The role of the SAB ...
    (Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... an August 2014 report by Global Research & Data ... 6.2% per year from 2014 through 2018, as demand ... United States is the world,s largest market ... market with advanced thermometers is Sanomedics International Holdings, Inc. ...
    (Date:10/22/2014)... AUSTIN, Texas , Oct. 22, ... today announced they have entered into a license ... designed to target cancers. PhosImmune possesses ... on the surfaces of tumor cells in association ... derived from proteins that play a role in ...
    Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
    ... Texas , May 3 US ... today launched new flexible offerings that can be customized ... practices. Through these expanded offerings, physicians can join more ... of US Oncology to work together to realign ...
    ... May 3 MAQUET Cardiovascular LLC today ... of the new VASOSHIELD Pressure Controlling Syringe for use ... syringe limits internal "flushing" pressure and controls vessel distension ... in bypass surgery. Avoiding excessive pressure and limiting distension ...
    Cached Medicine Technology:US Oncology Launches New Flexible Options for Community Oncologists to Join the United Network of US Oncology 2US Oncology Launches New Flexible Options for Community Oncologists to Join the United Network of US Oncology 3US Oncology Launches New Flexible Options for Community Oncologists to Join the United Network of US Oncology 4MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients 2MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients 3MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients 4
    (Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
    (Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
    (Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... may be showing a genetic propensity for obesity as toddlers, ... been linked to increased body fat, but the same genes ... the researchers said. At 1 year, kids with these ... 3, however, these genes were linked to excessive weight gain, ...
    (Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... men may lead to increased blood pressure, according to a ... rise in blood pressure for young adult women or for ... women drank lightly or moderately, their risk of high blood ... finding parallels studies in older adult men and women," said ...
    (Date:10/22/2014)... Dennis Thompson HealthDay Reporter , ... on Monday officially tightened guidelines for health workers treating Ebola ... and use of a respirator at all times. The ... the tougher rules after two Dallas nurses contracted Ebola while ... States, Liberian national Thomas Eric Duncan. Nina Pham is currently ...
    Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
    ... sales forces shrinking,across the pharmaceutical industry and physicians ... a place on hospital formularies has never been,more ... on,specialized training classes to help their reps better ... to recent,research from pharmaceutical benchmarking leader Best Practices, ...
    ... recent survey of 202 neonatologists and pediatricians, which examined ... health needs of preterm infants, revealed that most respondents ... not place enough emphasis on or dedicate enough resources ... by MedImmune, Inc. , The incidence of preterm birth, ...
    ... Feb. 19 Athletes for Life,Foundation (a District of ... ) have just completed their second mobile health screening ... largest such event in the,world, at its 35th anniversary., ... area donated,their time to care for the patients, conducting ...
    ... Transitionz Wellness,Boutique is a one-stop-shop for anyone, male ... survivor, is going through cancer treatments, or who ... and we are pleased to announce our Grand,Opening. ... services,including wigs, hats, turbans and scarves; breast forms, ...
    ... the brains of patients with schizophrenia also tend to ... the Silvio Conte Center for the Neuroscience of Mental ... Louis. Shape abnormalities were found in the brain,s thalamus. ... patients with schizophrenia and their non-affected siblings and compared ...
    ... in neurodevelopment may have yielded up a key secret. , ... says they have determined how events at the very tips ... back in the cell,s distant nucleus. , The study also ... that influence gene activity -- working outside the cell,s nucleus. ...
    Cached Medicine News:Health News:Building an Effective Sales Force to Serve the U.S. Hospital Market 2Health News:Neonatologists and pediatricians highlight progress and barriers to preemie care 2Health News:Neonatologists and pediatricians highlight progress and barriers to preemie care 3Health News:Signalife & Athletes Foundation Complete Second Mobile Health Screening 2Health News:Signalife & Athletes Foundation Complete Second Mobile Health Screening 3Health News:Transitionz Wellness Boutique Launches with Grand Opening Discounts 2Health News:Siblings of schizophrenia patients display subtle shape abnormalities in brain 2Health News:Scientists shed light on long-distance signaling in developing neurons 2Health News:Scientists shed light on long-distance signaling in developing neurons 3
    ThyroTest TSH is a rapid, qualitative test for hypothyroidism screening in adults....
    ... is an ultra-high speed, high resolution optical ... retina imaging and analysis. It ... Optical Coherence technology just emerging from clinical ... The ultra-high speed and high resolution ...
    ... the finest surgical-quality loupes available ... standard for innovative optical design, combining ... Delivering optimum performance with maximum comfort, ... for medical professionals worldwide. All SheerVision ...
    ... Experience the finest surgical-quality loupes available ... the standard for innovative optical design, ... support. Delivering optimum performance with maximum ... choice for medical professionals worldwide. All ...
    Medicine Products: